Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Some side effects usually do not require medical treatment and may resolve on their own as your body gradually adjusts to the medication.How severe are the side effects of Ivosiden···【more】
Article source：Captain MedicineRelease date：2025-12-31Recommended：171
Ivosidenib is also indicated for the treatment of myelodysplastic syndromes (MDS) that are relapsed or refractory to prior therapy.What side effects may Ivosidenib cause?While exer···【more】
Article source：Captain MedicineRelease date：2025-12-31Recommended：173
On December 26, 2017, Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leading company dedicated to treating cancer and rare genetic diseases by leveraging cellular metabolic mechanis···【more】
Article source：Captain MedicineRelease date：2025-12-31Recommended：200
The approval of ivosidenib for its indicated uses by the U.S. Food and Drug Administration (FDA) was supported by data from the ClarIDHy study. This is the first and only randomize···【more】
Article source：Captain MedicineRelease date：2025-12-31Recommended：155
The dosage of Ivosidenib may vary among different patients.What is the recommended dosage of Ivosidenib?Please follow the doctor’s instructions or the directions on the label. The ···【more】
Article source：Captain MedicineRelease date：2025-12-31Recommended：153
Ivosidenib is also indicated for the treatment of previously treated cholangiocarcinoma (biliary tract cancer) that has spread or is unresectable via surgery.Dosage and Administrat···【more】
Article source：Captain MedicineRelease date：2025-12-31Recommended：164
Ivosidenib is the first approved drug of the IDH1 inhibitor class. It works by inhibiting isocitrate dehydrogenase-1 (IDH1) to reduce the abnormal production of 2-hydroxyglutarate ···【more】
Article source：Captain MedicineRelease date：2025-12-31Recommended：162
Ivosidenib targets a specific gene mutation called IDH1, which may affect your bone marrow.What are the indications for Ivosidenib?The IDH1 mutation impairs the development of imma···【more】
Article source：Captain MedicineRelease date：2025-12-31Recommended：141
Ivosidenib can be used for the treatment of relapsed or refractory acute myeloid leukemia (AML) in patients who have received prior therapy. For such patients, conventional chemoth···【more】
Article source：Captain MedicineRelease date：2025-12-31Recommended：190
Ivosidenib, either as a monotherapy or in combination with azacitidine, is indicated for the treatment of newly diagnosed acute myeloid leukemia (AML) in patients aged ≥ 75 years o···【more】
Article source：Captain MedicineRelease date：2025-12-31Recommended：179
Tibsovo® (ivosidenib tablets) is the first tumor metabolism-targeted therapy approved for use in combination with azacitidine for the treatment of adult patients with newly diagnos···【more】
Article source：Captain MedicineRelease date：2025-12-31Recommended：170
On October 24, 2023, Servier, a leader in the oncology field dedicated to bringing tomorrow’s hope to patients, announced today that the U.S. Food and Drug Administration (FDA) has···【more】
Article source：Captain MedicineRelease date：2025-12-31Recommended：195
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：4502025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：6372024-09-07
On May 28, 2026, AstraZeneca announced that its immunotherapy drug Imfinzi (durvalumab) in combinati···【more】
Recommended：942026-01-06
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：4162025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：4382025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：4242025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：4772025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：3862025-01-12
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Name: Lucius
Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643
